The Relationship Between COVID and Cognitive Function

Post by Anastasia Sares

The takeaway

A new meta-analysis showed that having COVID-19 (even a mild to moderate case) was linked to lower performance on cognitive tests after a person was no longer infected. Severe cases were linked to worse performance than mild or moderate cases. This is part of a larger pattern for viral diseases in general. 

What’s the science?

Getting infected with SARS-CoV-2—the virus that causes COVID-19—can lead to symptoms like fatigue and brain fog, which sometimes last long after a person has recovered from the virus itself. In light of these symptoms, it is important to understand what effect COVID-19 may have on the public's long-term cognitive health. We need to know whether people’s self-reported cognitive issues correspond to actual performance on cognitive tests—in other words, an objective cognitive impact. Many studies were published on this topic during the years of the pandemic, but to better understand the trends, we need more than a lot of individual studies. Each study has slightly different methods and is conducted on a different group of people. Meta-analysis is a technique that takes the results from many different studies and aggregates them to help us come to an overall conclusion.

Recently in Neuropsychology Review, Austin and colleagues conducted a meta-analysis to understand the objective cognitive effects of COVID-19 infection.

How did they do it?

The authors sifted through multiple databases of scientific literature using keywords related to Sars-Cov-2/COVID and cognitive functioning, searching specifically for studies that evaluated cognition after the initial acute phase of the disease. They eliminated studies that were duplicates, did not address their main questions, did not involve mild to moderate COVID cases, or did not include objective measures of cognitive functioning (among other criteria). Then, they divided the studies into three categories: first, those that compared cognitive performance between a non-COVID control group and a mild-COVID group, second, those that compared the performance of a mild COVID group to an established testing norm, and third, a group mild or moderate COVID versus a group with severe COVID symptoms. The prediction was that the COVID groups would perform worse overall than the standardized norms as well as the control groups and that severe COVID would lead to worse performance than mild or moderate COVID. 

What did they find?

In all three groups, scores across the cognitive testing spectrum were lower for the COVID groups. Memory, language, and combined measures were significantly affected. In addition, the groups with severe COVID performed worse than those with mild or moderate COVID in attention, memory, and executive function. However, visuospatial functioning was not affected. It is important to mention that the size of these effects was not large and differed quite a bit across studies; they were most pronounced in those with long-lasting symptoms after their illness. The authors gave some possible explanations for why COVID might lead to cognitive symptoms. The virus could have direct effects on brain tissue, or it may contribute indirectly via neural inflammation and other stress-induced processes. People may also experience distraction due to ongoing physical pain or depressive symptoms. These ideas are based on what we know about similar dynamics in other viral diseases such as influenza, herpes, and hepatitis. Ultimately, there are many questions left to be answered, especially as this virus evolves and changes over time.

What’s the bottom line?

As COVID-19 transitions from being pandemic (new and spreading out of control) to endemic (constantly present in the population but more predictable), it is important to understand how it affects cognitive health, especially since the population is also aging in many countries. Given this new risk to cognitive health, it is more important than ever to focus on finding therapies that can prevent or slow cognitive decline.

Access the original scientific publication here.

Home-Based Brain Stimulation for Treating Depression

Post by Soumilee Chaudhuri

The takeaway

This study tested a non-invasive at-home device that uses a portable version of transcranial direct current stimulation (tDCS) for people with major depressive disorder (MDD). In a 10-week trial, adults with moderate depression who used the device showed more remarkable symptom improvement than those who did not. The device proved safe, effective, and easy to manage from home with remote support, suggesting it could be a valuable new option for treating depression.

What's the science?

Major depressive disorder (MDD) is a severe mental health condition characterized by persistent sadness, loss of interest in daily activities, and disturbances in sleep, appetite, and energy levels. It is typically treated with antidepressant medications and psychotherapy. However, about one-third of people with MDD do not fully respond to these treatments. Transcranial direct current stimulation (tDCS) is a non-invasive alternative that uses a mild electrical current to stimulate specific brain areas involved in mood regulation. This is typically done by placing electrodes on the scalp of one's head, with one electrode applying a small positive current and the other using an opposing current. This stimulative process can help improve brain function by adjusting the excitation level of these critical brain regions. Additionally, tDCS is portable and potentially more accessible, and previous studies have shown that it can improve depression symptoms, but most have required in-person visits. Therefore, this study aimed to test whether a 10-week at-home version of tDCS, with remote monitoring, could be an effective and practical solution for treating depression.

How did they do it?

The study enrolled one hundred seventy-four participants (120 women, 54 men) with a mean age of 37.63 years, all of whom met the criteria for MDD as defined by the Diagnostic and Statistical Manual of Mental Disorders. The participants were randomly assigned to one of two groups: the active tDCS treatment group and the placebo (sham) group, where the device did not work. Both groups had 87 people each, and the treatment lasted for 10 weeks. Most participants were on stable medication or therapy before joining the study.

What did they find?

Over 10 weeks, participants who received active tDCS demonstrated significant improvements in depression-related outcomes, including reductions in overall symptom severity and higher rates of response to treatment or remission, compared to those receiving the sham treatment. On average, scores on the Hamilton Depression Rating Scale (HDRS) in people in the active group went down by approximately 9 points, in contrast with a decrease of 7 points in the placebo group. The active treatment group had more participants (58%) whose symptoms improved by at least half, compared to just 38% in the placebo group. The active tDCS group also exhibited 2 to 3 times higher symptom improvement rates than the sham group. As the study included individuals with varying types of depression, including first-episode depression, recurrent depression, and treatment-resistant depression, these results indicated that tDCS was beneficial across all subgroups of MDD. Compared to prior studies in the field with shorter treatment protocols, the current study's 10-week treatment period showed better results in decreasing symptoms of depression. Additionally, while some participants experienced mild side effects, such as skin irritation at the stimulation site, these were rare and were not serious or long-term.

What's the impact?

This study aimed to evaluate the effectiveness of a 10-week home-based transcranial direct current stimulation (tDCS) as a treatment for Major Depressive Disorder (MDD) in adults. The results provide strong evidence that home-based tDCS is an effective and safe intervention for reducing depressive symptoms. This makes it a promising alternative for individuals with MDD, including those with treatment-resistant forms of the disorder or who might not have easy access to traditional in-person therapy. The findings of this study could significantly impact the field of depression treatment, offering a new, accessible, and effective option for those who do not respond to traditional therapies. 

Access the original scientific publication here

Sleep Loss Affects Developing Synapses in the Brain

Post by Baldomero B. Ramirez Cantu

The takeaway

Sleep is essential for brain health, especially during development. This study found that sleep deprivation disrupts key processes in brain maturation, with juvenile mice showing significantly higher vulnerability than adults. 

What's the science?

Sleep is crucial for lifelong cognitive health, particularly during brain development. Synapses in the brain undergo significant transformations during youth, shifting from high synapse formation in juveniles to stability in adulthood. Neurodevelopmental conditions like autism spectrum disorder (ASD) often show early-life sleep disturbances, making sleep loss during sensitive developmental periods an important focus. This week in PNAS, Gay et al. investigated the molecular and behavioral impact of sleep deprivation (SD) across developmental stages in mice, analyzing differences in how juvenile, adolescent, and adult brains respond to sleep loss.

How did they do it?

The study involved juvenile, adolescent, and adult mice, which underwent a 4 or 6 hour sleep deprivation session at the start of the light phase. Researchers assessed memory using a novel object recognition (NOR) task, where only juveniles showed cognitive impairment after SD, indicating that adults were more resilient to the deprivation.

For molecular analysis, the team collected forebrain synaptic proteins from each age group under sleep, wake, and SD conditions, using mass spectrometry to quantify thousands of proteins and phosphoproteins. Statistical analysis revealed that SD in juveniles led to broad changes in synapse-related proteins involved in growth and plasticity, whereas adolescents and adults had fewer alterations. Further analysis highlighted that the SD-sensitive proteins in juveniles strongly overlapped with autism risk genes, suggesting that early sleep disruption may interact with genetic vulnerabilities during brain development.

What did they find?

Juvenile mice exposed to SD showed cognitive impairments in memory tasks, whereas adults remained largely unaffected. At the synaptic level, SD was associated with protein and phosphorylation changes in juvenile mice, including upregulation of proteins linked to synaptogenesis and neural activity. These responses overlapped with ASD risk genes, suggesting a potential interaction between developmental sleep loss and ASD susceptibility.

What's the impact?

The findings underscore the role of sleep in neural development and the potential risks posed by sleep loss in youth, with implications for neurodevelopmental disorders like ASD. These insights could guide public health recommendations for pediatric sleep hygiene and inform approaches to ASD prevention and treatment by emphasizing sleep as a crucial factor in brain health.